Details for Patent: 9,775,851

« Back to Dashboard

Which drugs does patent 9,775,851 protect, and when does it expire?

Patent 9,775,851 protects SERNIVO and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 9,775,851

Title:	Topical formulations comprising a steroid
Abstract:	The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Inventor(s):	Udhumansha Ubaidulla, Sateesh Kandavilli, Ajay Sunil Vairale, Jeffrey A. Wayne, Vijendra Nalamothu, Mistry Meghal, Refika Isil Pakunlu
Assignee:	PRIMUS PHARMACEUTICALS Inc
Application Number:	US15/495,148
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,775,851
Patent Claim Types: see list of patent claims	Use; Composition; Device;

Drugs Protected by US Patent 9,775,851

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079-001	Feb 5, 2016		RX	Yes	Yes			Y			TREATMENT OF PLAQUE PSORIASIS

Foreign Priority and PCT Information for Patent: 9,775,851

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
India	2111/CHE/2009	Aug 31, 2009

International Family Members for US Patent 9,775,851

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Denmark	2473161
European Patent Office	2473161
European Patent Office	3141246
Japan	2013503203